Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/54414
Campo DC Valoridioma
dc.contributor.authorMarathe, Chaitraen_US
dc.contributor.authorBradley, Michelle N.en_US
dc.contributor.authorHong, Cynthiaen_US
dc.contributor.authorLopez, Felixen_US
dc.contributor.authorRuiz De Galarreta, Carlos M.en_US
dc.contributor.authorTontonoz, Peteren_US
dc.contributor.authorCastrillo, Antonioen_US
dc.date.accessioned2019-02-18T10:38:52Z-
dc.date.available2019-02-18T10:38:52Z-
dc.date.issued2006en_US
dc.identifier.issn0021-9258en_US
dc.identifier.urihttp://hdl.handle.net/10553/54414-
dc.description.abstractThe liver X receptors (LXRs) are ligand-dependent transcription factors that have been implicated in lipid metabolism and inflammation. LXRs also inhibit the expression of inflammatory genes in macrophages, including inducible nitric oxide synthase (iNOS). Some of these actions are mediated through LXR antagonism of NF-kappa B activity. The potential for LXRs to positively regulate the expression of anti-inflammatory molecules, however, has not been explored. Here we show that the arginase II (ArgII) gene is a direct target for LXR regulation. ArgII catalyzes the conversion of L-arginine into L-ornithine and urea, leading to the synthesis of polyamines. Expression of ArgII is induced by LXR agonists in macrophage cell lines and primary murine macrophages in a receptor-dependent manner. The ArgII promoter contains a functional LXR response elements that mediates promoter induction by LXR/RXR (retinoid X receptor) in transfection assays. Since ArgII and iNOS utilize a common substrate, induction of ArgII expression has the potential to exert anti-inflammatory effects by shifting arginine metabolism toward polyamine synthesis at the expense of NO production. In support of this hypothesis, we demonstrate that forced expression of ArgII mimics the inhibitory effect of LXR activation on macrophage NO production. Furthermore, inhibition of arginase activity partially reverses the inhibitory effect of LXR agonists on NO production. These studies suggest that regulation of ArgII may contribute to the immunomodulatory effects of LXRs.en_US
dc.languagespaen_US
dc.publisher0021-9258
dc.relationSaf2005-03270. Los Receptores Lxr y Su Papel en la Respuesta Inflamatoria, Inmunitaria y Apoptótica.en_US
dc.relation.ispartofJournal of Biological Chemistryen_US
dc.sourceJournal of Biological Chemistry[ISSN 0021-9258],v. 281, p. 32197-32206en_US
dc.subject.otherInterferon Regulatory Factor-3
dc.subject.otherNitric-Oxide Synthase
dc.subject.otherL-Arginine
dc.subject.otherDifferential Regulation
dc.subject.otherReciprocal Regulation
dc.subject.otherNuclear Receptors
dc.subject.otherLipid-Metabolism
dc.subject.otherMouse Model
dc.subject.otherLxr
dc.subject.otherCholesterol
dc.titleThe arginase II gene is an anti-inflammatory target of liver X receptor in macrophagesen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1074/jbc.M605237200en_US
dc.identifier.scopus33845934193-
dc.identifier.isi000241414500017-
dc.contributor.authorscopusid6507337761-
dc.contributor.authorscopusid7202096772-
dc.contributor.authorscopusid15755660400-
dc.contributor.authorscopusid7202047893-
dc.contributor.authorscopusid6602478628-
dc.contributor.authorscopusid7003806034-
dc.contributor.authorscopusid7007079890-
dc.contributor.authorscopusid55445301000-
dc.description.lastpage32206en_US
dc.description.firstpage32197en_US
dc.relation.volume281en_US
dc.type2Artículoen_US
dc.contributor.daisngid4210757-
dc.contributor.daisngid2210915-
dc.contributor.daisngid750105-
dc.contributor.daisngid2864371-
dc.contributor.daisngid1664323-
dc.contributor.daisngid103250-
dc.contributor.daisngid225640-
dc.contributor.wosstandardWOS:Marathe, C-
dc.contributor.wosstandardWOS:Bradley, MN-
dc.contributor.wosstandardWOS:Hong, C-
dc.contributor.wosstandardWOS:Lopez, F-
dc.contributor.wosstandardWOS:de Galarreta, CMR-
dc.contributor.wosstandardWOS:Tontonoz, P-
dc.contributor.wosstandardWOS:Castrillo, A-
dc.date.coverdateOctubre 2006en_US
dc.identifier.ulpgces
dc.description.jcr5,808
dc.description.jcrqQ1
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0003-1167-9787-
crisitem.author.orcid0000-0002-2057-2159-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameLópez Blanco, Félix-
crisitem.author.fullNameCastrillo Viguera, Antonio Jesús-
crisitem.project.principalinvestigatorCastrillo Viguera, Antonio Jesús-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

82
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

83
actualizado el 17-nov-2024

Visitas

154
actualizado el 23-nov-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.